JP2013531028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531028A5 JP2013531028A5 JP2013519183A JP2013519183A JP2013531028A5 JP 2013531028 A5 JP2013531028 A5 JP 2013531028A5 JP 2013519183 A JP2013519183 A JP 2013519183A JP 2013519183 A JP2013519183 A JP 2013519183A JP 2013531028 A5 JP2013531028 A5 JP 2013531028A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- ylbenzenesulfonamide
- phenoxy
- fluoro
- thiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229940124777 Nav1.7 inhibitor Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- VHPXWPAGHGHDCK-UHFFFAOYSA-N 5-chloro-4-[(3,4-dichlorophenoxy)methyl]-2-fluoro-n-methylsulfonylbenzamide Chemical compound C1=C(F)C(C(=O)NS(=O)(=O)C)=CC(Cl)=C1COC1=CC=C(Cl)C(Cl)=C1 VHPXWPAGHGHDCK-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- -1 3-Amino-1H-pyrazol-4-yl Chemical group 0.000 claims 1
- GRKVYZKIYFQNRJ-UHFFFAOYSA-N 3-cyano-4-[2-(3-methylpyridazin-4-yl)-4-(trifluoromethyl)phenoxy]-n-(1,2,4-thiadiazol-5-yl)benzenesulfonamide Chemical compound CC1=NN=CC=C1C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(S(=O)(=O)NC=2SN=CN=2)C=C1C#N GRKVYZKIYFQNRJ-UHFFFAOYSA-N 0.000 claims 1
- WUAXPBQBULMOPU-UHFFFAOYSA-N 3-methyl-4-[2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-n-(1,2,4-thiadiazol-5-yl)benzenesulfonamide Chemical compound CC1=CC(S(=O)(=O)NC=2SN=CN=2)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C1=CC=NN=C1 WUAXPBQBULMOPU-UHFFFAOYSA-N 0.000 claims 1
- PHTUVTNPUXCTAT-UHFFFAOYSA-N 4-[2-(2-aminopyridin-4-yl)-4-(trifluoromethyl)phenoxy]-5-chloro-2-fluoro-n-(5-fluoropyrimidin-2-yl)benzenesulfonamide Chemical compound C1=NC(N)=CC(C=2C(=CC=C(C=2)C(F)(F)F)OC=2C(=CC(=C(F)C=2)S(=O)(=O)NC=2N=CC(F)=CN=2)Cl)=C1 PHTUVTNPUXCTAT-UHFFFAOYSA-N 0.000 claims 1
- SQDDFKWDMWPJHU-UHFFFAOYSA-N 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-3-chloro-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound C1=NC(N)=CC(C=2C(=CC=C(Cl)C=2)OC=2C(=CC(=CC=2)S(=O)(=O)NC=2SC=NN=2)Cl)=C1 SQDDFKWDMWPJHU-UHFFFAOYSA-N 0.000 claims 1
- GWJXHLNIPCOZMP-UHFFFAOYSA-N 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-n-(1,3-thiazol-4-yl)benzenesulfonamide Chemical compound C1=NC(N)=CC(C=2C(=CC=C(Cl)C=2)OC=2C(=CC(=C(F)C=2)S(=O)(=O)NC=2N=CSC=2)Cl)=C1 GWJXHLNIPCOZMP-UHFFFAOYSA-N 0.000 claims 1
- UPXLXDDNAJGXRJ-UHFFFAOYSA-N 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-n-(5-fluoropyrimidin-2-yl)benzenesulfonamide Chemical compound C1=NC(N)=CC(C=2C(=CC=C(Cl)C=2)OC=2C(=CC(=C(F)C=2)S(=O)(=O)NC=2N=CC(F)=CN=2)Cl)=C1 UPXLXDDNAJGXRJ-UHFFFAOYSA-N 0.000 claims 1
- JQXWXDMMTRVMIO-UHFFFAOYSA-N 4-[2-(2-aminopyridin-4-yl)-4-fluorophenoxy]-5-chloro-2-fluoro-n-(1,3-thiazol-4-yl)benzenesulfonamide Chemical compound C1=NC(N)=CC(C=2C(=CC=C(F)C=2)OC=2C(=CC(=C(F)C=2)S(=O)(=O)NC=2N=CSC=2)Cl)=C1 JQXWXDMMTRVMIO-UHFFFAOYSA-N 0.000 claims 1
- MLOOHDGWBBEIMG-UHFFFAOYSA-N 4-[2-(5-amino-1h-pyrazol-4-yl)-4-fluorophenoxy]-5-chloro-2-fluoro-n-(1,3-thiazol-4-yl)benzenesulfonamide Chemical compound N1N=CC(C=2C(=CC=C(F)C=2)OC=2C(=CC(=C(F)C=2)S(=O)(=O)NC=2N=CSC=2)Cl)=C1N MLOOHDGWBBEIMG-UHFFFAOYSA-N 0.000 claims 1
- WMQBUKSBQANZPY-UHFFFAOYSA-N 4-[4-chloro-2-(2-piperazin-1-ylpyridin-4-yl)phenoxy]-2,5-difluoro-n-pyrimidin-2-ylbenzenesulfonamide Chemical compound FC1=CC(S(=O)(=O)NC=2N=CC=CN=2)=C(F)C=C1OC1=CC=C(Cl)C=C1C(C=1)=CC=NC=1N1CCNCC1 WMQBUKSBQANZPY-UHFFFAOYSA-N 0.000 claims 1
- GINGGBAKMBEXER-UHFFFAOYSA-N 4-[4-chloro-2-(2-piperazin-1-ylpyridin-4-yl)phenoxy]-3-cyano-n-pyrimidin-2-ylbenzenesulfonamide Chemical compound C=1C=NC(N2CCNCC2)=CC=1C1=CC(Cl)=CC=C1OC(C(=C1)C#N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 GINGGBAKMBEXER-UHFFFAOYSA-N 0.000 claims 1
- QPSLEIYZLBXWQO-UHFFFAOYSA-N 4-[4-chloro-2-(2-piperazin-1-ylpyrimidin-4-yl)phenoxy]-2,5-difluoro-n-(1,3-thiazol-4-yl)benzenesulfonamide Chemical compound FC1=CC(S(=O)(=O)NC=2N=CSC=2)=C(F)C=C1OC1=CC=C(Cl)C=C1C(N=1)=CC=NC=1N1CCNCC1 QPSLEIYZLBXWQO-UHFFFAOYSA-N 0.000 claims 1
- RGIZNVIZLKVVQR-UHFFFAOYSA-N 4-[4-chloro-2-(2-piperazin-1-ylpyrimidin-4-yl)phenoxy]-2,5-difluoro-n-pyrimidin-2-ylbenzenesulfonamide Chemical compound FC1=CC(S(=O)(=O)NC=2N=CC=CN=2)=C(F)C=C1OC1=CC=C(Cl)C=C1C(N=1)=CC=NC=1N1CCNCC1 RGIZNVIZLKVVQR-UHFFFAOYSA-N 0.000 claims 1
- PMMZOISISCRBGJ-UHFFFAOYSA-N 4-[4-chloro-2-(2-piperazin-1-ylpyrimidin-4-yl)phenoxy]-3-cyano-n-pyrimidin-2-ylbenzenesulfonamide Chemical compound C=1C=NC(N2CCNCC2)=NC=1C1=CC(Cl)=CC=C1OC(C(=C1)C#N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 PMMZOISISCRBGJ-UHFFFAOYSA-N 0.000 claims 1
- SSMHJQAOMIOGQL-UHFFFAOYSA-N 4-[6-[2-(azetidin-3-yl)pyrazol-3-yl]-3-chloro-6-fluoro-4-(trifluoromethyl)cyclohexa-2,4-dien-1-yl]oxy-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(F)(C=2N(N=CC=2)C2CNC2)C1OC(C=C1)=CC=C1S(=O)(=O)NC1=NN=CS1 SSMHJQAOMIOGQL-UHFFFAOYSA-N 0.000 claims 1
- PEWVRSYQZDWQAV-UHFFFAOYSA-N 5-chloro-2-fluoro-4-[2-[2-(1-methylazetidin-3-yl)pyrazol-3-yl]-4-(trifluoromethyl)phenoxy]-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound C1N(C)CC1N1C(C=2C(=CC=C(C=2)C(F)(F)F)OC=2C(=CC(=C(F)C=2)S(=O)(=O)NC=2SC=NN=2)Cl)=CC=N1 PEWVRSYQZDWQAV-UHFFFAOYSA-N 0.000 claims 1
- ARQKOCRSOZQOQY-UHFFFAOYSA-N 5-chloro-2-fluoro-4-[2-pyridazin-4-yl-4-(trifluoromethoxy)phenoxy]-n-(1,3-thiazol-4-yl)benzenesulfonamide Chemical compound ClC=1C=C(S(=O)(=O)NC=2N=CSC=2)C(F)=CC=1OC1=CC=C(OC(F)(F)F)C=C1C1=CC=NN=C1 ARQKOCRSOZQOQY-UHFFFAOYSA-N 0.000 claims 1
- YKGKGGRESIDHTA-UHFFFAOYSA-N 5-chloro-2-fluoro-4-[4-fluoro-2-pyridazin-4-yl-5-(trifluoromethyl)phenoxy]-n-(1,3-thiazol-4-yl)benzenesulfonamide Chemical compound C1=C(C(F)(F)F)C(F)=CC(C=2C=NN=CC=2)=C1OC(C(=C1)Cl)=CC(F)=C1S(=O)(=O)NC1=CSC=N1 YKGKGGRESIDHTA-UHFFFAOYSA-N 0.000 claims 1
- DVUWUVKNVJRGOH-UHFFFAOYSA-N 5-chloro-2-fluoro-4-[5-fluoro-2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-n-(1,3-thiazol-4-yl)benzenesulfonamide Chemical compound C=1C=NN=CC=1C=1C=C(C(F)(F)F)C(F)=CC=1OC(C(=C1)Cl)=CC(F)=C1S(=O)(=O)NC1=CSC=N1 DVUWUVKNVJRGOH-UHFFFAOYSA-N 0.000 claims 1
- JPASNGLELUOECE-UHFFFAOYSA-N 5-chloro-4-[4-chloro-2-(2-piperazin-1-ylpyrimidin-4-yl)phenoxy]-2-fluoro-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound ClC=1C=C(S(=O)(=O)NC=2SC=NN=2)C(F)=CC=1OC1=CC=C(Cl)C=C1C(N=1)=CC=NC=1N1CCNCC1 JPASNGLELUOECE-UHFFFAOYSA-N 0.000 claims 1
- IAKKNZCQDXKWBM-UHFFFAOYSA-N 5-chloro-4-[4-chloro-2-(2-piperazin-1-ylpyrimidin-4-yl)phenoxy]-2-fluoro-n-(1,3-thiazol-4-yl)benzenesulfonamide Chemical compound ClC=1C=C(S(=O)(=O)NC=2N=CSC=2)C(F)=CC=1OC1=CC=C(Cl)C=C1C(N=1)=CC=NC=1N1CCNCC1 IAKKNZCQDXKWBM-UHFFFAOYSA-N 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36290410P | 2010-07-09 | 2010-07-09 | |
| US61/362,904 | 2010-07-09 | ||
| PCT/IB2011/052840 WO2012004706A2 (en) | 2010-07-09 | 2011-06-28 | Chemical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531028A JP2013531028A (ja) | 2013-08-01 |
| JP2013531028A5 true JP2013531028A5 (https=) | 2014-07-24 |
| JP5872552B2 JP5872552B2 (ja) | 2016-03-01 |
Family
ID=44532968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519183A Expired - Fee Related JP5872552B2 (ja) | 2010-07-09 | 2011-06-28 | 化学化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9145407B2 (https=) |
| EP (1) | EP2590972B1 (https=) |
| JP (1) | JP5872552B2 (https=) |
| CA (1) | CA2804173C (https=) |
| ES (1) | ES2532356T3 (https=) |
| WO (1) | WO2012004706A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012004714A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| EP2593433B1 (en) | 2010-07-12 | 2014-11-26 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| JP6014155B2 (ja) * | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| KR102038607B1 (ko) | 2012-10-15 | 2019-10-30 | 주식회사 대웅제약 | 소디움 채널 차단제, 이의 제조방법 및 이의 용도 |
| JP2015535252A (ja) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物 |
| WO2014086704A1 (en) | 2012-12-03 | 2014-06-12 | F. Hoffmann-La Roche Ag | Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1) |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| CA2900604A1 (en) * | 2013-03-15 | 2014-09-25 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| UA120353C2 (uk) | 2013-09-10 | 2019-11-25 | Хромоселл Корпорейшн | Модулятори натрієвого каналу для лікування болю і діабету |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| CA2950393A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| WO2016034971A1 (en) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Sulfonamides derivatives as urat1 inhibitors |
| WO2016040315A1 (en) * | 2014-09-09 | 2016-03-17 | Chromocell Corporation | Selective nav1.7 inhibitors for the treatment of diabetes |
| HK1252567A1 (zh) | 2015-05-22 | 2019-05-31 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| AU2016370554B2 (en) | 2015-12-18 | 2018-11-29 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| PE20190980A1 (es) | 2016-10-17 | 2019-07-09 | Genentech Inc | Compuestos terapeuticos y metodos para utilizarlos |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| WO2019217822A1 (en) * | 2018-05-11 | 2019-11-14 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| EP3891157A4 (en) | 2018-12-05 | 2022-08-31 | Merck Sharp & Dohme Corp. | 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS |
| WO2020248123A1 (en) | 2019-06-11 | 2020-12-17 | Merck Sharp & Dohme Corp. | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905971A (en) | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
| DE3531919A1 (de) | 1985-09-07 | 1987-03-19 | Hoechst Ag | Substituierte 2-phenyl-hexahydro-1,2,4-triazin-3,5-dione, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| DE3540654A1 (de) | 1985-11-13 | 1987-05-14 | Schering Ag | Phenoxy-substituierte ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel |
| US5591761A (en) | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DE69206725T2 (de) | 1991-09-10 | 1996-05-02 | Zeneca Ltd | Benzolsulfonamidderivate als 5-Lipoxygenasehemmer |
| GB2263635A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substitiuted triazoles as neurotensin antagonists |
| US5219856A (en) | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
| NZ247440A (en) | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| CA2257206A1 (en) | 1996-06-07 | 1997-12-11 | Gui-Bai Liang | Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity |
| US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP0937723A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| EP1041072B1 (en) | 1999-03-31 | 2003-07-16 | Pfizer Products Inc. | Dioxocyclopentyl hydroxamic acids |
| HN2000000052A (es) | 1999-05-28 | 2001-02-02 | Pfizer Prod Inc | Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos. |
| WO2000073295A1 (en) | 1999-05-28 | 2000-12-07 | Pfizer Products Inc. | 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
| AU6180600A (en) | 1999-07-29 | 2001-02-19 | Ono Pharmaceutical Co. Ltd. | Sulfonamide derivatives and remedies for allodynia |
| EP1088819B1 (en) | 1999-09-30 | 2005-06-15 | Pfizer Products Inc. | 6-azauracil derivatives as thyroid receptor ligands |
| WO2001056989A2 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| CN1251671C (zh) | 2000-05-19 | 2006-04-19 | 武田药品工业株式会社 | β分泌酶抑制剂 |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| AU2002347336A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
| WO2003059265A2 (en) | 2001-12-21 | 2003-07-24 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| MXPA05001592A (es) | 2002-08-09 | 2005-05-05 | Astrazeneca Ab | Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico. |
| US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| CN102146053A (zh) | 2003-03-24 | 2011-08-10 | 阿克西金药品公司 | 治疗哮喘及其它炎症或免疫性疾病的具有ccr3拮抗活性的2-苯氧基-和2-苯基磺酰胺衍生物 |
| WO2004103980A1 (en) | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
| US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| US8202861B2 (en) | 2003-08-08 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| US20070082907A1 (en) | 2003-11-25 | 2007-04-12 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| KR20060109937A (ko) | 2003-12-15 | 2006-10-23 | 니뽄 다바코 산교 가부시키가이샤 | Ｎ-치환-ｎ-술포닐아미노시클로프로판 화합물 및 그의약제학적 용도 |
| CN1956983B (zh) | 2004-05-24 | 2010-05-26 | 弗·哈夫曼-拉罗切有限公司 | 4-羟基-4-甲基-哌啶-1-甲酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺 |
| WO2006002284A1 (en) | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| MX2007001215A (es) | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
| EP1790637B1 (en) | 2004-09-13 | 2014-01-29 | Ono Pharmaceutical Co., Ltd. | Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient |
| SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| WO2006060762A2 (en) | 2004-12-03 | 2006-06-08 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| ES2440965T3 (es) | 2005-01-14 | 2014-01-31 | Chemocentryx, Inc. | Heteroaril-sulfonamidas y CCR2 |
| WO2006089311A1 (en) | 2005-02-15 | 2006-08-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP1899299B1 (en) | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| DE602006020871D1 (de) | 2005-06-27 | 2011-05-05 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden |
| NZ566136A (en) | 2005-09-23 | 2010-04-30 | Pfizer Prod Inc | Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) |
| CA2624726A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| EP1948597A1 (en) | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| AR058296A1 (es) | 2005-12-09 | 2008-01-30 | Kalypsys Inc | Inhibidores de histona desacetilasa y composicion farmaceutica |
| EP1979348B1 (en) | 2005-12-21 | 2012-01-18 | Abbott Laboratories | Anti-viral compounds |
| JP5232987B2 (ja) | 2006-04-14 | 2013-07-10 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアリールオキシエチルアミン化合物 |
| GB0608386D0 (en) | 2006-04-27 | 2006-06-07 | Senexis Ltd | Compounds |
| CA2656067C (en) | 2006-06-23 | 2014-08-12 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| EP2089365A1 (en) | 2006-10-05 | 2009-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derived metalloprotease inhibitors |
| US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
| WO2008050200A1 (en) | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| CA2695613A1 (en) | 2006-12-19 | 2008-06-26 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
| EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| JP5361857B2 (ja) | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | イオンチャネルの阻害剤 |
| US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| PE20090288A1 (es) | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | Derivados de quinoxalina como inhibidores de la pi3 quinasa |
| CA2693588C (en) | 2007-07-13 | 2015-11-17 | Icagen, Inc. | Sodium channel inhibitors |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| EP2220065A2 (en) | 2007-07-30 | 2010-08-25 | Encysive Pharmaceuticals, Inc. | Modulators of ccr9 receptor and methods of use thereof |
| BRPI0820171B8 (pt) | 2007-11-16 | 2021-05-25 | Rigel Pharmaceuticals Inc | compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos |
| MX2010011258A (es) | 2008-04-14 | 2011-06-20 | Univ Texas | Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos. |
| US20110071197A1 (en) | 2008-04-16 | 2011-03-24 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
| HUE025013T2 (hu) * | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| WO2012004714A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| EP2593433B1 (en) | 2010-07-12 | 2014-11-26 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| JP2013532184A (ja) * | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
-
2011
- 2011-06-28 JP JP2013519183A patent/JP5872552B2/ja not_active Expired - Fee Related
- 2011-06-28 US US13/808,625 patent/US9145407B2/en not_active Expired - Fee Related
- 2011-06-28 ES ES11743357.3T patent/ES2532356T3/es active Active
- 2011-06-28 CA CA2804173A patent/CA2804173C/en not_active Expired - Fee Related
- 2011-06-28 EP EP11743357.3A patent/EP2590972B1/en not_active Not-in-force
- 2011-06-28 WO PCT/IB2011/052840 patent/WO2012004706A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531028A5 (https=) | ||
| JP2013543896A5 (https=) | ||
| AR109816A2 (es) | Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2 | |
| JP2015524472A5 (https=) | ||
| JP2010515715A5 (https=) | ||
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| JP2012530705A5 (https=) | ||
| JP2015508749A5 (https=) | ||
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| IL202018A (en) | 4,2-Difluoro-n- {2- (Methylaoxy) -5- [4- (4-Pyridazinyl) -6-Quinolinyl] -3-Pyridinyl} Benzenesulfonamide, its Pharmaceuticals and Its Use in the Treatment of Pi3 Kinase-Related Diseases | |
| JP2010529118A5 (https=) | ||
| MX346186B (es) | Inhibidores de proteina cinasas. | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| NZ602125A (en) | Uses of dgat1 inhibitors | |
| JP2012507535A5 (https=) | ||
| JP2009511450A5 (https=) | ||
| JP2009532438A5 (https=) | ||
| MA37455B1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JP2020529995A5 (https=) | ||
| JP2013087119A5 (https=) | ||
| BR112014011518A2 (pt) | liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida | |
| BR112014009165A8 (pt) | sal e uso médico | |
| AR109652A1 (es) | Métodos para utilizar agonistas de fxr |